Brainstorm Cell Therapeutics Inc

Change company Symbol lookup

Select an option...

BCLI Brainstorm Cell Therapeutics Inc

EEX Emerald Holding Inc

JPM-L JPMorgan Chase & Co

SBFM Sunshine Biopharma Inc

SEKEY Seiko Epson Corp

PXMD PaxMedica Inc

CDT Conduit Pharmaceuticals Inc

FUSN Fusion Pharmaceuticals Inc

RDUS Schnitzer Steel Industries Inc

ALEC Alector Inc

Go

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimers disease (AD) and other neurodegenerative diseases. NurOwn, the Company’s cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its Phase III ALS and Phase II PMS clinical trials. Its wholly owned Israeli subsidiary, BrainStorm Cell Therapeutics Ltd., holds rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd. and two others.